{
    "eid": "2-s2.0-85082146369",
    "title": "Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors",
    "cover-date": "2020-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Internal Medicine",
            "@code": "2724",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Endocrinology, Diabetes and Metabolism",
            "@code": "2712",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Mariam Alatrach",
        "Nitchakarn Laichuthai",
        "Robert Martinez",
        "Christina Agyin",
        "Ali Muhammed Ali",
        "Hussein Al-Jobori",
        "Olga Lavynenko",
        "John Adams",
        "Curtis Triplitt",
        "Ralph DeFronzo",
        "Eugenio Cersosimo",
        "Muhammad Abdul-Ghani"
    ],
    "citedby-count": 18,
    "ref-count": 17,
    "ref-list": [
        "Renal, metabolic and cardiovascular considerations of SGLT2 inhibition",
        "Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus",
        "Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production",
        "Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy",
        "Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes",
        "Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients",
        "Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo",
        "Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion",
        "Glucagon levels during short-term SGLT2 inhibition are largely regulated by glucose changes in patients with type 2 diabetes",
        "No direct effect of SGLT2 activity on glucagon secretion",
        "Combination therapy with canagliflozin plus liraglutide exerts synergistic effect on weight loss, but not on HbA1c in T2DM patients",
        "Studies on the mechanism of action of somatostatin on renal gluconeogenesis: Evidence for the involvement of alpha 1-adrenergic stimuli",
        "Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog",
        "Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man",
        "Regulation of hepatic glucose metabolism in health and disease",
        "Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes",
        "The effect of somatostatin on central hemodynamics, renal blood flow, and renal function in dogs"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "San Antonio",
            "@id": "60018573",
            "affilname": "University of Texas Health Science Center at San Antonio",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018573",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Lilly Diabetes Alliance",
        "National Institutes of Health",
        "National Institute of Diabetes and Digestive and Kidney Diseases",
        "Boehringer Ingelheim",
        "AstraZeneca",
        "Merck",
        "Janssen Pharmaceuticals",
        "Intarcia Therapeutics",
        "Novo Nordisk"
    ]
}